Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but ...
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to ...
Strategic Financial Concepts LLC acquired a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The ...
Hosted on MSN5d
Why NeoGenomics (NEO) Shares Are Trading Lower TodayWhat Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session ...
Q4 2024 Earnings Call Transcript February 18, 2025 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.04, ...
NeoGenomics (NASDAQ:NEO – Get Free Report) had its price objective decreased by analysts at Needham & Company LLC from $19.00 to $18.00 in a report released on Wednesday,Benzinga reports.
NeoGenomics (NASDAQ:NEO – Get Free Report) had its target price reduced by Bank of America from $19.00 to $16.00 in a research note issued on Wednesday,Benzinga reports.The brokerage currently ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback